Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Clinical manifestation of mitochondrial diseases

M. Magner, H. Kolářová, T. Honzik, I. Švandová, J. Zeman,

. 2015 ; 19 (4) : 441-449.

Jazyk angličtina Země Polsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc16021008

Grantová podpora
NT14156 MZ0 CEP - Centrální evidence projektů

Mitochondrial disorders (MD) represent a clinically, biochemically and genetically heterogeneous group of diseases associated with dysfunction of the oxidative phosphorylation system and pyruvate dehydrogenase complex. Our aim was to illustrate the most common clinical presentation of MD on the example of selected diseases and syndromes. The minimal prevalence of MD is estimated as 1 to 5,000. MD may manifest at any age since birth until late-adulthood with acute manifestation or as a chronic progressive disease. Virtually any organ may be impaired, but the organs with the highest energetic demands are most frequently involved, including brain, muscle, heart and liver. Some MD may manifest as a characteristic cluster of clinical features (e.g. MELAS syndrome, Kearns-Sayre syndrome). Diagnostics includes detailed history, the comprehensive clinical examination, results of specialized examinations (especially cardiology, visual fundus examination, brain imaging, EMG), laboratory testing of body fluids (lactate, aminoacids, organic acids), and analysis of bioptic samples of muscle, skin, and liver, eventually. Normal lactate level in blood does not exclude the possibility of MD. Although the aimed molecular genetic analyses may be indicated in some of mitochondrial diseases, the methods of next generation sequencing come into focus. Examples of treatment are arginine supplementation in MELAS syndrome, ketogenic diet in pyruvate oxidation disorders or quinone analogs in patients with LHON. Conclusion: The clinical suspicion of a mitochondrial disorder is often delayed, or the disease remains undiagnosed. The correct diagnosis and adequate treatment can improve prognosis of the patient. Access to genetic counseling is also of great importance.

000      
00000naa a2200000 a 4500
001      
bmc16021008
003      
CZ-PrNML
005      
20190902103152.0
007      
ta
008      
160722s2015 pl f 000 0|eng||
009      
AR
035    __
$a (PubMed)26982751
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Magner, Martin $7 xx0084624
245    10
$a Clinical manifestation of mitochondrial diseases / $c M. Magner, H. Kolářová, T. Honzik, I. Švandová, J. Zeman,
520    9_
$a Mitochondrial disorders (MD) represent a clinically, biochemically and genetically heterogeneous group of diseases associated with dysfunction of the oxidative phosphorylation system and pyruvate dehydrogenase complex. Our aim was to illustrate the most common clinical presentation of MD on the example of selected diseases and syndromes. The minimal prevalence of MD is estimated as 1 to 5,000. MD may manifest at any age since birth until late-adulthood with acute manifestation or as a chronic progressive disease. Virtually any organ may be impaired, but the organs with the highest energetic demands are most frequently involved, including brain, muscle, heart and liver. Some MD may manifest as a characteristic cluster of clinical features (e.g. MELAS syndrome, Kearns-Sayre syndrome). Diagnostics includes detailed history, the comprehensive clinical examination, results of specialized examinations (especially cardiology, visual fundus examination, brain imaging, EMG), laboratory testing of body fluids (lactate, aminoacids, organic acids), and analysis of bioptic samples of muscle, skin, and liver, eventually. Normal lactate level in blood does not exclude the possibility of MD. Although the aimed molecular genetic analyses may be indicated in some of mitochondrial diseases, the methods of next generation sequencing come into focus. Examples of treatment are arginine supplementation in MELAS syndrome, ketogenic diet in pyruvate oxidation disorders or quinone analogs in patients with LHON. Conclusion: The clinical suspicion of a mitochondrial disorder is often delayed, or the disease remains undiagnosed. The correct diagnosis and adequate treatment can improve prognosis of the patient. Access to genetic counseling is also of great importance.
650    _2
$a mozek $x patofyziologie $7 D001921
650    _2
$a mitochondriální DNA $x analýza $7 D004272
650    _2
$a elektroencefalografie $7 D004569
650    _2
$a lidé $7 D006801
650    _2
$a Kearnsův-Sayreův syndrom $x diagnóza $x patofyziologie $7 D007625
650    _2
$a syndrom MELAS $x diagnóza $x patofyziologie $7 D017241
650    _2
$a syndrom MERRF $x diagnóza $x patofyziologie $7 D017243
650    _2
$a mitochondriální nemoci $x diagnóza $x patofyziologie $7 D028361
650    _2
$a mitochondriální encefalomyopatie $x diagnóza $x patofyziologie $7 D017237
650    _2
$a mitochondriální myopatie $x diagnóza $x patofyziologie $7 D017240
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kolářová, Hana $7 xx0227560
700    1_
$a Honzík, Tomáš $7 xx0075651
700    1_
$a Švandová, Ivana
700    1_
$a Zeman, Jiří $u Department of Paediatrics and Adolescent Medicine, Ke Karlovu 2, 128 08 Praha 2, Czech Republic
773    0_
$w MED00189519 $t Developmental period medicine $x 1428-345X $g Roč. 19, č. 4 (2015), s. 441-449
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26982751 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20190902103520 $b ABA008
999    __
$a ok $b bmc $g 1155678 $s 945536
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 19 $c 4 $d 441-449 $i 1428-345X $m Developmental period medicine $n Dev Period Med $x MED00189519
GRA    __
$a NT14156 $p MZ0
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...